CLIENT ALERT

When a global pharmaceutical leader like Novartis commits $12 billion to acquire Avidity Biosciences, the signal to the biotech community is clear: RNA-based therapeutics are moving from promise to proven platform.

This deal, one of the largest of 2025, gives Novartis access to Avidity’s RNA conjugate technology and a late-stage pipeline of drugs for muscular dystrophy. But for biotech innovators and early-stage companies, the story behind this transaction is even more important: the market is rewarding strong science backed by clear, defensible intellectual property.

1. RNA Is Entering Its Next Phase and IP Is the Differentiator

Avidity’s platform addresses one of RNA therapy’s most challenging barriers: delivering drugs to tissues beyond the liver. The company’s proprietary antisense oligonucleotide conjugates (AOCs) enable RNA-based treatments to target muscle tissue, a major advance for diseases like Duchenne and myotonic dystrophy.

For smaller biotechs developing delivery systems, vector chemistries, or targeting technologies, this deal underscores a key point: innovation in RNA delivery is where the value, and acquisition potential: lies.

But it also highlights a critical need: IP precision.
Platforms like Avidity’s succeed not just because of the science, but because their patent portfolios clearly define and protect what makes their delivery method distinct, from linker chemistry to payload conjugation to tissue specificity.

2. Investors and Acquirers Are Looking for Clarity and Coverage

In a consolidating biotech market, acquirers are prioritizing assets with clean, enforceable, and strategically layered IP protection. Novartis’ decision to pay a 46% premium for Avidity reflects confidence in both the underlying data and the patent position.

For early-stage companies, that means:

• Conducting freedom-to-operate analyses early to anticipate blocking patents.

• Filing continuations or divisionals to strengthen coverage as platforms evolve.

• Protecting not only compositions and methods but also delivery mechanisms, manufacturing processes, and data-driven targeting algorithms.

At Wood IP, we often help clients translate their R&D into layered portfolios that can withstand the kind of diligence that drives deals like this.

3. How Smaller Innovators Can Position Themselves

For emerging biotech companies, the Novartis–Avidity deal highlights a playbook for growth:

Build proprietary platforms, not just assets.
Avidity didn’t sell a single drug; it sold a delivery technology with wide application. That kind of scalable platform attracts premium valuations.

Prioritize defensibility early.
When your discovery pipeline relies on a novel mechanism, documenting inventive steps and maintaining clear ownership of underlying data is essential.

Think modular IP.
Protect the parts of your system, conjugation methods, targeting ligands, carrier molecules, not just the finished product. This modular approach creates flexibility for partnerships and licensing.

Wood IP’s Perspective

At Wood IP, we partner with biotechnology innovators to:

• Map and protect platform-level inventions in RNA, gene, and cell therapies.

• Strengthen IP documentation and chain of title ahead of funding or M&A events.

• Leverage AI tools to identify claim gaps and predict examination outcomes in complex biotech filings.

Our team’s background in both biotech and software-driven IP allows us to guide clients through emerging intersections, where biology meets data, and precision meets protection.

Key Takeaways

• Novartis’ $12B Avidity acquisition marks growing market confidence in RNA therapeutics.

• The value of platform companies now rests as much in IP clarity as clinical promise.

• Startups can increase strategic value through layered, defensible patent portfolios.

• A forward-looking IP strategy can transform R&D momentum into acquisition readiness.

Closing Thought

As RNA therapeutics expand beyond the liver, competition for differentiated delivery technologies will intensify. The companies that succeed won’t just innovate; they’ll own their innovation.